Advertisements

Astonin-H

Quick links to important sections

Astonin-H

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Astonin-H

Quick Facts

Property Description
Active ingredient Fludrocortisone acetate
Form Oral tablets
Pharmacological class Synthetic mineralocorticoid / Corticosteroid
Common use Hormone replacement therapy for adrenal insufficiency
Origin Synthetic analogue (fluorinated derivative)

What Type of Medicine is Astonin-H (Fludrocortisone)?

Astonin-H is a prescription-only medicine whose active ingredient is Fludrocortisone acetate, delivered as an oral tablet for systemic activity. The medication is classified within the pharmacological class of corticosteroids, but it is primarily distinguished as a potent mineralocorticoid. Under this classification, the drug’s dominant function is to manage fluid and salt balance, acting similarly to a natural hormone. The compound itself is a synthetic analogue and a fluorinated derivative of natural adrenocortical hormones, a modification recognized for enhancing the necessary mineralocorticoid effect compared to the body’s natural counterparts. As a single-ingredient formulation containing only Fludrocortisone acetate, Astonin-H is fundamentally defined by this highly specific therapeutic profile.

How Does Astonin-H Support Key Bodily Functions?

The general therapeutic purpose of Astonin-H is to serve as replacement therapy for conditions resulting from the body's insufficient production of adrenal hormones, often termed adrenocortical insufficiency. This function is critical for maintaining stability, as fludrocortisone helps keep the body from losing too much salt. The drug achieves this by exerting a strong mineralocorticoid effect, primarily by acting on the kidneys to restore and manage the essential electrolyte balance. This mechanism causes the necessary retention of sodium and water while promoting the excretion of potassium, actions vital for upholding stable blood volume and ensuring reliable circulatory stability—a common use scenario for supporting patients with primary hypoaldosteronism. This precise management of fluids and electrolytes is key to its role in sustaining life-critical functions.

Advertisements

What side effects are possible with Astonin-H?

Possible side effects and safety information

The safety profile of Astonin-H (fludrocortisone acetate) is defined by its potent mineralocorticoid activity, as documented in official government regulatory information.

Key Safety Domains and Systemic Effects

Adverse reactions are primarily linked to the management of fluid and electrolyte balance. The most common or expected effects involve Sodium and Water Retention, potentially leading to Hypertension (high blood pressure) and Hypokalemia (low potassium levels).

Regulatory documents categorize possible adverse reactions across several System-Organ Classes, including:

System-Organ Class Example Adverse Reaction Areas
Metabolism & Nutrition Fluid/electrolyte disturbances
Cardiac & Vascular Hypertension, Congestive Heart Failure
Musculoskeletal Osteoporosis, Muscle Weakness
Gastrointestinal Peptic Ulceration, Abdominal Distention
Endocrine HPA Axis Suppression, Growth Retardation

Serious Adverse Reactions and Duration-Related Safety

Official prescribing information notes the potential for serious adverse reactions, including the induction or exacerbation of Congestive Heart Failure and serious Peptic Ulceration (with perforation risk). The risk of certain conditions is specifically associated with the duration of exposure.

Long-term use is linked to the development of HPA axis suppression (secondary adrenal unresponsiveness), osteoporosis, and cataracts/glaucoma. This time-related pattern helps structure the understanding of chronic risk.

Population-Specific Safety and Restrictions

Safety notes include specific considerations for vulnerable groups. For the pediatric population, official labels specify the risk of growth retardation. Furthermore, the medicine is contraindicated in individuals with a systemic fungal infection, defining a key safety restriction established in regulatory guidelines.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Astonin-H (fludrocortisone acetate) is officially documented to present with signs of exaggerated mineralocorticoid activity. These manifestations include hypertension (elevated blood pressure), edema (swelling), excessive increase in weight, and hypokalemia (low potassium levels). Other documented clinical signs of overdosage are an increase in heart size ( cardiomegaly) and muscular weakness resulting from the excessive loss of potassium.

Required Emergency Response

Government regulatory authorities mandate seeking immediate medical attention if an overdose is suspected, even if symptoms are not yet present. Urgent contact with emergency services (e.g., 911 or equivalent), a hospital emergency department, or a regional poison control centre is required. This action is critical if the affected individual exhibits severe symptoms such as collapse, seizure, trouble breathing, or inability to be awakened.

Management and Monitoring

There is no specific antidote formally listed for fludrocortisone acetate overdosage. Official management procedures involve discontinuing the medication and administering symptomatic and supportive treatment. This includes providing a potassium supplement to address hypokalemia. Regulatory information states that the overdose symptoms typically subside within several days after the drug is stopped or the dose is reduced.

Advertisements

Therapeutic Uses of Astonin-H

What Astonin-H Treats: Main Uses and Benefits

Astonin-H (fludrocortisone acetate) is a medication used to help manage symptoms related to systemic imbalance. It is commonly used across conditions characterized by periods of heightened symptoms, such as Addison’s disease and salt-losing adrenogenital syndrome, applied in clinical settings that involve systemic imbalance.

Managing Core Symptom Domains

This medication is generally relevant when supportive symptom management is appropriate for conditions associated with acute or disruptive episodes. Astonin-H may assist with maintaining functional stability by addressing the primary symptom clusters, including low blood pressure and associated dizziness, severe fatigue and muscle weakness, and disturbances in fluid and salt balance.

“It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

Key Therapeutic Benefits

Astonin-H plays a role in managing the overall symptom burden by helping to stabilize the circulation and support the retention of vital sodium and water. This support contributes to improved day-to-day comfort during symptomatic periods, applied in scenarios where additional management of discomfort is required.


Quick Fact: Relief for Dizziness and Weakness (Astonin-H is commonly used to help manage the severe dizziness and fatigue linked to hormonal and electrolyte imbalance.)

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Astonin-H?

Eligibility for Astonin-H (fludrocortisone acetate) is defined by official regulatory documentation, outlining specific populations for whom the medicine is permitted, restricted, or strictly prohibited. The medication is officially approved for populations requiring mineralocorticoid replacement therapy, such as those with Addison’s disease.

Absolute Contraindications

The medicine must not be used by individuals with systemic fungal infections or a known hypersensitivity to fludrocortisone acetate or any component of the formulation. Additionally, patients receiving immunosuppressive dosages of the medication must not receive live virus vaccines.

Conditional Use and Restrictions

Use requires caution in several patient groups due to the risk of exacerbating pre-existing conditions. These restrictions apply to patients with renal insufficiency or hepatic impairment, as well as those with hypertension or congestive heart failure due to the drug's sodium-retaining effects. Use in patients with active tuberculosis is also strictly conditioned.

Age and Reproductive Status

Safety and effectiveness have not been established in pediatric patients. For older adults, the use requires caution due to the greater frequency of decreased organ function. In pregnancy, Astonin-H is classified as Category C and is to be given only if clearly needed. Caution is advised when administering the drug to nursing women.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Astonin-H (fludrocortisone acetate) based on pharmacokinetic (PK) and pharmacodynamic (PD) effects, as well as specific procedural restrictions. The drug's use is prohibited when co-administered with Live Virus Vaccines due to the potential for neurological complications and a compromised antibody response. Use is also restricted in the presence of Systemic Fungal Infections.

Documented Interaction Patterns

Metabolic Clearance: Certain medicines may reduce the effect of fludrocortisone by accelerating its breakdown. For example, co-administration with enzyme inducers such as Barbiturates, Phenytoin, or Rifampin increases the drug’s metabolic clearance through hepatic enzyme induction, leading to reduced exposure.

Electrolyte Balance: Pharmacodynamic interactions can enhance the medicine's effect on electrolytes. Co-administration with Potassium-depleting Diuretics (e.g., Furosemide, Thiazides) or Amphotericin B results in enhanced hypokalemia (excessive potassium loss). This increased risk of low potassium, when combined with Digitalis Glycosides, can enhance the possibility of arrhythmias. Furthermore, Anabolic Steroids may increase the tendency toward edema (fluid retention).

Other Interactions: The official label also notes that Aspirin (Salicylates) co-administration increases the ulcerogenic effect on the gastrointestinal system. Fludrocortisone increases the susceptibility of the stomach to the irritating effects of alcohol.

Advertisements

Mechanism of Action

Mineralocorticoid Receptor Activation and Ion Transport

The drug's primary action is highly targeted: it is an agonist that binds to the intracellular Mineralocorticoid Receptor (MR). This binding triggers a change in gene expression in the kidney tubules, resulting in the increased synthesis of transport proteins like the Epithelial Sodium Channel ( ENaC) and the Na^+/ K^+-ATPase pump. This mechanism initiates the reabsorption of sodium ( Na^+) from the urine back into the bloodstream, while simultaneously promoting the coupled excretion of potassium ( K^+) and hydrogen ions ( H^+).


Fluid Volume Expansion and Circulatory Homeostasis

The active retention of Na^+ generates an osmotic gradient, causing water to passively follow the sodium ions, thereby expanding the extracellular fluid volume and the overall plasma volume. This volume expansion is a core physiological effect that contributes to circulatory volume and influences blood pressure. Furthermore, the MR and GR agonism provides a significant negative feedback signal to the Hypothalamic-Pituitary-Adrenal ( HPA) axis, suppressing the body's endogenous corticosteroid production.

Advertisements

Dosage and Administration Information

Astonin-H (fludrocortisone acetate) is intended for oral administration as a systemic hormone replacement therapy. The medication is typically supplied in the 0.1 mg tablet form, and the standard regimen involves taking the dose once daily. Although the tablets are often scored, the score line may be intended to assist in swallowing and not for accurate dose division.

Dosing is highly individualized and must be continuously adjusted based on the patient's physiological response. The usual daily maintenance dose for adults is 0.1 mg, though dosing regimens may range from 0.1 mg three times a week up to 0.2 mg daily to establish stability. If clinical monitoring reveals fluid imbalance, such as the development of transient hypertension, the dose may be reduced to 0.05 mg daily.

As a partial replacement agent, Astonin-H is required to be administered concomitantly with a glucocorticoid when used for conditions like adrenocortical insufficiency. The proper use of this drug demands ongoing monitoring of key physiological indicators, including blood pressure and serum electrolyte levels, to ensure the dose remains appropriate. Because therapy is generally long-term, the protocol dictates that any cessation of the drug must be managed by a gradual reduction (tapering) over weeks or months. Furthermore, patients on continuous systemic therapy must be administered a supplemental dose during periods of major physical stress, such as severe illness or surgery.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Astonin-H


Evidence for Use in Primary Adrenocortical Insufficiency

Astonin-H was studied for use in conditions like Addison's disease, where the body's adrenal glands do not produce enough natural hormones. Because this is an essential replacement therapy, the evidence base does not primarily consist of large, blinded, placebo-controlled trials. Instead, research relies on clinical practice guidelines developed by experts and longitudinal observational studies of patient cohorts over many years.

The research examined critical outcomes related to systemic or functional imbalance, mainly focusing on markers used to monitor replacement therapy, such as plasma renin activity (PRA), which is a key biological indicator, and the stability of serum electrolyte levels (sodium and potassium). Findings in these cohorts describe patterns observed in the evolution of these markers over time.

Evidence for Use in Congenital Adrenal Hyperplasia (CAH)

The use of this medicine for conditions associated with acute or disruptive episodes, such as the salt-wasting form of Congenital Adrenal Hyperplasia (CAH), was evaluated in specific patient populations. Research here relies heavily on established clinical consensus guidelines and retrospective audits that review long-term approaches.

In this context, studies explored the factors associated with the risk of acute adrenal crisis/circulatory collapse and focused on monitoring sodium balance in the most vulnerable patients. Research examined outcomes in neonates, infants, and young children through careful monitoring of serum electrolyte levels and plasma renin activity. Studies report how symptoms evolved in the observed populations, and the data show patterns related to the changes measured during the study period for these parameters.

What Is Still Uncertain About Astonin-H Evidence

Scientific research highlights what is known — and what is still uncertain—about the use of this medicine. One key uncertainty is the variability in findings related to optimal dosing, especially in neonates with CAH where research is ongoing to refine understanding.

Furthermore, while the evidence base for its role in hormone replacement is established by clinical consensus guidelines, the evidence quality varies across studies for its use in conditions like orthostatic hypotension, where comparative evidence is lacking in large randomized controlled trials. Across all uses, research provides context but not individual predictions of response.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Astonin-H (FAQ)


Q: How quickly should I expect Astonin-H to start working?

Official information indicates that the initial effects on the body's mineralocorticoid activity—which involves managing sodium and potassium levels—may be observed over the course of one to two days following a single dose. Achievement of the full, stable therapeutic response typically requires ongoing monitoring and dose adjustment, as described in prescribing information.


Q: What are the most common side effects of Astonin-H?

According to official product information, the most common or expected effects are related to the drug’s function on fluid balance. These include an increase in blood pressure (hypertension), fluid retention (edema), and potential lowering of potassium levels, known as hypokalemia.


Q: Can Astonin-H cause weight gain?

Yes, official documentation notes that this medication can lead to unusual weight gain. This effect is primarily due to the drug's mechanism causing the body to retain sodium and water, which results in an increase in fluid volume and retention.


Q: Are there any common over-the-counter medicines that interact with Astonin-H?

Official regulatory warnings note potential interactions with common pain relievers. The concurrent use of Astonin-H with Aspirin (salicylates) or NSAIDs like ibuprofen may increase the risk of serious side effects, specifically ulceration and bleeding in the stomach and intestines.


Q: Is it possible to be allergic to Astonin-H?

Yes, the medication is contraindicated (must not be used) in patients who have a known history of hypersensitivity to fludrocortisone acetate or other corticosteroids. Hypersensitivity is the clinical term used to describe an allergic reaction.


Q: Why is it described that users should limit potassium intake with Astonin-H?

The premise of limiting potassium intake is generally incorrect. The drug's mechanism causes the body to lose potassium while retaining sodium. Because of this, official sources often advise that patients may need potassium supplementation to prevent levels from dropping too low. Regulatory information indicates that the need for any dietary adjustment is determined by a healthcare provider.


Q: Does Astonin-H require a special prescription or monitoring program?

Astonin-H is a prescription-only medicine for which ongoing monitoring is typically advised. Official documentation advises the periodic checking of serum electrolyte levels (salt and potassium) and close supervision of blood pressure and body weight to ensure the dose remains correct and stable.


Q: Can Astonin-H be taken with common pain relievers like ibuprofen?

Regulatory information indicates caution is needed. Taking Astonin-H alongside nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may increase the chance of developing gastrointestinal side effects, including ulceration.


Q: Is it normal to have swelling in the ankles when taking Astonin-H?

Swelling in the lower legs or ankles is a potential side effect. This is related to the drug's strong effect of promoting fluid retention (edema). If this effect is observed, it is typically evaluated as part of routine monitoring.


Q: Is Astonin-H a type of blood pressure medication?

Astonin-H is classified as a mineralocorticoid/corticosteroid used for hormone replacement. While its effect on sodium retention does influence blood pressure, its primary function is not to treat high blood pressure. In fact, official warnings state that doses must be carefully monitored to avoid the development of hypertension (high blood pressure).


Q: Is Astonin-H the same as florinef?

Yes, they are essentially the same product. Fludrocortisone acetate is the active ingredient in Astonin-H, and it is also the active ingredient in the brand-name medication Florinef (Florinef Acetate). Different countries or manufacturers may use different trade names for the same active compound.


Q: Will Astonin-H make me feel dizzy or tired?

Regulatory documentation lists dizziness as a possible adverse reaction. Additionally, unexplained or severe tiredness may be a symptom of an underlying issue, such as an electrolyte imbalance or adrenal insufficiency. These symptoms are typically subject to clinical evaluation by a healthcare provider.


Q: Can people with diabetes safely use Astonin-H?

Official warnings state that Astonin-H should be administered cautiously in patients with diabetes mellitus. Corticosteroids like fludrocortisone can cause hyperglycemia (high blood sugar) and may worsen existing diabetes or may cause previously undiagnosed diabetes to appear.


Q: Is Astonin-H suitable for older adults?

The use of the drug in older adults requires caution. Official warnings note that the common adverse effects of systemic corticosteroids, such as hypertension and bone density loss, may be associated with more serious consequences in older age. Close clinical supervision is necessary.


Q: What happens if I stop taking Astonin-H suddenly?

Stopping this medication suddenly can be dangerous. Abrupt discontinuation may lead to a medical emergency known as acute adrenal insufficiency (or Addisonian crisis). This condition is potentially life-threatening and involves severe drops in blood pressure and critical electrolyte disruption.


Q: Do I need to change my diet while I am on Astonin-H?

Due to the drug’s effects on salt and water balance, official guidance may advise certain dietary changes. This could include sodium restriction and possibly potassium supplementation. The necessity of these changes is determined by a healthcare provider based on individual monitoring results.


Q: Is there a generic version of Astonin-H available?

Yes, the active ingredient, fludrocortisone acetate, is available under its generic name. Astonin-H is simply one of the brand names for the medication.


Q: Can Astonin-H affect my sleep patterns?

Official reports of undesirable effects list insomnia (trouble sleeping) as a possible adverse reaction. Any significant or disruptive change in sleep patterns should be noted as part of routine monitoring.


Q: Does Astonin-H impact mood or cause anxiety?

Yes, official documentation includes changes in mental status as possible side effects. These reactions can include anxiety, mood swings, and depression.


Q: Does Astonin-H contain lactose or gluten?

Regulatory documentation for the tablet formulation explicitly confirms that the medicine contains lactose as an excipient. Patients who have certain rare hereditary problems, such as galactose intolerance, are advised not to take the medicine. Gluten is not specified in the official composition.


Q: How often is the effectiveness of Astonin-H usually checked?

The effectiveness is checked through regular monitoring. Official documentation advises the periodic checking of serum electrolyte levels and close supervision of blood pressure and weight to ensure that the medication is providing the correct level of hormone replacement.


Q: Can Astonin-H affect laboratory blood test results?

Yes, official product information indicates that the drug can influence specific lab test results. Specifically, it may increase the serum sodium level and may decrease the potassium level.


Q: Will taking Astonin-H affect my ability to drive?

Official prescribing information includes a section dedicated to the Effects on ability to drive and use machines. As side effects like dizziness and vision changes are possible, patients are advised to be cautious until the effects of the medication are known.


Q: What should I look out for if I think I'm having a serious side effect from Astonin-H?

Patients are advised to monitor for certain symptoms that may indicate a serious reaction. These can include significant swelling of the face or lower legs, severe headache, or sudden vision problems. Any suspected serious side effect or severe illness typically warrants immediate medical evaluation.


Q: How long can a person typically stay on Astonin-H therapy?

Astonin-H is prescribed as a partial hormone replacement therapy for chronic conditions like adrenal insufficiency. Regulatory documentation indicates that for these uses, treatment is generally considered long-term.


Q: Does Astonin-H cause changes in blood sugar?

Yes, as a corticosteroid, the medication has the potential to cause hyperglycemia (high blood sugar). Official warnings state that it can affect blood sugar control in people with diabetes or even precipitate latent diabetes.

Advertisements

How should Astonin-H be stored and disposed of?

How to Store and Dispose of Astonin-H (Fludrocortisone Acetate Tablets)

Astonin-H must be stored refrigerated within a strict temperature range of 2 C to 8 C, maintaining a shelf life of 24 months. The original container must be kept tightly closed to ensure the tablets are protected from moisture.

Stability and Handling Constraints

The product is permitted a single temperature excursion up to 25 C for a maximum of 30 days. Following this, any unused tablets must be disposed of and must not be returned to refrigerated storage. For safety, the medicine must always be stored out of the reach and sight of children.

Disposal

Disposal of unused or expired product, including tablets remaining after a temperature excursion, must be completed according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Astonin-H found in:

A-Z Index: